Pulmonary Thromboembolism is the clinical entity due to the obstruction of pulmonary vessels by venous thrombi, leading to nonspecific clinical manifestations, making it difficult to early diagnosis. Predisposition results from genetic and acquired factors contributing to the venous thromboembolism. When the diagnosis of Pulmonary Thromboembolism (PT) is confirmed and effective therapy is instituted, the recurrence of embolism is rare and death is usually uncommon, with mortality rate around 20–30%.
KeywordsPulmonary thromboembolism Vessels Diagnosis Anticoagulation
- 1.Heit JA, Cohen AT, Anderson FA, VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the U. S. Blood. 2005;107:277a.Google Scholar
- 5.Endorsed by the European Respiratory Society (ERS). Eur Heart J. 2014;35(43):3033–73. https://doi.org/10.1093/eurheartj/ehu283.
- 7.Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756–64.PubMedGoogle Scholar
- 10.Eur Heart J. 2014;35:3033–80. doi: https://doi.org/10.1093/eurheartj/ehu283.